Weight Loss Drugs Reshape Consumer Spending Across Multiple Industries

Dramatic Shifts in Food and Restaurant Spending

Americans taking GLP-1 weight loss medications are fundamentally changing how they spend money, creating ripple effects across entire industries. The medications are associated with meaningful reductions in how much households spend on food, both at the grocery store and at restaurants. U.S. households with at least one person using GLP-1 drugs reduced grocery store spending by about 6% during the six months following adoption, while higher-income households over $125,000 cut spending by nearly 9%.

The changes aren't uniform across all food categories. Ultra-processed, calorie-dense foods – the kinds most closely associated with cravings – saw the sharpest declines. Sales of chips, baked goods and packaged cookies per consumer fell an average of 6.7 to 11 percent in their first six months on the medication. Restaurant habits are shifting too, with users reduced their spending on dining out by 8.6 percent and fast-food restaurants saw a slight decline in breakfast sales, according to Leo Feler, chief economist at Numerator, while dinner sales saw a 6 percent decline.

Perhaps most striking is the impact on alcohol consumption. Users spent 14.5 percent less in the category after starting the treatment, while nonalcoholic wine and beer purchases among the group ballooned by 1,158 and 935 percent, respectively. This shift reflects the broader appetite-suppressing effects of these medications that extend beyond just food cravings.

Fashion and Beauty Industries Capitalize on Body Changes

Weight-loss drugs create an opportunity for clothing brands as consumers refresh their wardrobe while they shed pounds. The data shows concrete changes in purchasing patterns: Demand for women's tops in extra small and small sizes rose two percentage points from 2022 to 2024 and were down two percentage points for large and extra large sizes. Meanwhile, formal-wear sales surged 80 percent and sporting goods jumped 24 percent in the first six months of 2025 compared with the same period last year.

The beauty and wellness sectors are also benefiting. While weight loss GLP-1 users tend to spend more in the store overall, especially early in, Health and Beauty Care is an area experiencing sizable gains. GLP-1 users are also gaining confidence and boosting their spending on beauty products and new clothes to go out in. This confidence boost appears to be driving increased spending across multiple lifestyle categories as users feel better about their appearance.

Fitness and Healthcare Sector Adaptations

Gyms and fitness centers are rapidly adapting their business models to serve this growing market. Equinox has a "GLP-1 protocol," with dedicated lifestyle and training coaches, while Planet Fitness has curated workout guides on its website. Life Time, a health club chain, has opened clinics that include personal trainers and doctors who can prescribe the medications.

The healthcare landscape is experiencing significant changes as well. Bariatric surgeries declined 25.6% between 2022 and 2023, with GLP-1 prescriptions up 132.6% during the same period. This shift represents a fundamental change in how obesity treatment is approached, moving from surgical interventions to pharmaceutical solutions.

Long-Term Economic Implications

With the share of U.S. households reporting at least one user rose from about 11% in late 2023 to more than 16% by mid-2024, the economic impact continues to expand. However, there's a crucial caveat: about one-third of users stopped taking the medication during the study period. When they did, their food spending reverted to pre-adoption levels – and their grocery baskets became slightly less healthy than before they started.

The scale of change is unprecedented for a pharmaceutical intervention. As adoption grows and new applications for the drugs come to light, experts say that could have sweeping outcomes for both health and the economy. Companies across industries are now forced to reconsider their business models, from food manufacturers developing "GLP-1 friendly" products to retailers adjusting inventory for changing size distributions. This pharmaceutical revolution is proving that medical breakthroughs can reshape consumer behavior in ways that extend far beyond their intended health benefits.